Hypogonadism, also known as gonad deficiency, is a disease that involves less or no production of sex hormones. The different types of the hypogonadism include primary hypogonadism and central hypogonadism or secondary hypogonadism. The disease is caused by several factors including autoimmune disorders, genetic disorders, severe infections, liver and kidney diseases, undescended testes, radiation exposure, hemochromatosis, pituitary disorders, inflammatory diseases, obesity, nutritional deficiencies and surgery. Lipocine Inc. is in the process of developing LPCN 1021 for the treatment of hypogonadism. The drug candidate is being developed as an oral product candidate of testosterone, containing testosterone undecanoate that is designed to help restore normal testosterone levels in males for conditions associated with a deficiency or absence of endogenous testosterone. Some of the companies having a pipeline of hypogonadism include Ferring International Center S.A., Repros Therapeutics Inc. and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities, including information about clinical results, designations, collaborations, licencing, grants, technology and others.